BioXcel Therapeutics, Inc. (BTAI) Monday said it has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding the planned sNDA submission for IGALMI. Following the news, the company's shares were more than 30% up in pre-market.
The FDA feedback confirmed agreement on the content and format for the company's sNDA submission to expand the IGALMI label for the At-Home setting. BioXcel's IGALMI is currently approved for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in medically supervised settings.
The company plans to submit sNDA for IGALMI in the first quarter of 2026.
BioXcel stock had closed at $5.48, up 15.37% on Friday. Ithas traded in the range of $1.17 - $13.36 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.